secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0000950170-22-008972
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q1 net loss $13.4M; cash $361.2M; IND filed for JANX007
-------------------------------------------------------------

- Net loss of $13.4M for Q1 2022 vs. $2.3M in Q1 2021; R&D spend $10.2M, G&A $4.9M.
- Cash & investments $361.2M at March 31, 2022, down from $375.0M at Dec 31, 2021.
- IND submitted for PSMA-TRACTr (JANX007); IND for EGFR-TRACTr (JANX008) expected 2H 2022.
- Merck nominated a second target under the 2020 collaboration agreement in May 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022008972/0000950170-22-008972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022008972/janx-20220510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer